chrisvoncsefalvay/vaers-outcomes huggingface dataset:
aches all over; headache; weakness in legs and arms; no energy; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (aches all over), HEADACHE (headache), ASTHENIA (weakness in legs and arms) and ASTHENIA (no energy) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced MYALGIA (aches all over), HEADACHE (headache), ASTHENIA (weakness in legs and arms) and ASTHENIA (no energy). At the time of the report, MYALGIA (aches all over), ASTHENIA (weakness in legs and arms) and ASTHENIA (no energy) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
red, inflamed, warm to touch & swelling 1x2" @ inj site 12-14hr p/vax;
At time of injection, patient said she felt sharp pain in her arm that she alerted to the administering pharmacist.  The patient is a nurse and said she felt the pharmacist administered the shot appropriately/in the appropriate muscle and did not know why she experienced the pain.  The pharmacist told her that maybe the vaccine was not fully warm yet.  The patient went home and later noticed a red slightly swollen area between 2-3 inches in diameter and 3-4 inches in length appear further down her upper arm.  The direct injection site was not red or swollen.  She attempted to ice the area, but said it was too painful so she left it alone.  She reported trouble sleeping due to the pain in her arm.  She presented to the pharmacy at 5:30PM on 5/20 to show me the red area on her arm.  I suggested she may want to have it checked out by an MD, but she said she did not want to do that at the time.  I recommended that she take some ibuprofen and benadryl to reduce the soreness and redness and either apply an ice pack or a cold damp cloth to the effected skin to reduce symptoms.  The patient said it was feeling slightly better than the day of injection.  She has not experienced any noticeable issues with range of motion.  She was very pleasant and explained that she had previous reactions of redness at injection site and soreness when receiving her COVID vaccinations.  We discussed that the appearance of the symptoms actually looks pretty similar to what has previously been seen in "COVID arm."  I did tell her that if the symptoms worsened she definitely should get checked by a physician, but she said she is heading out of town the next morning and would take the benadryl/ibuprofen combo before bed and see how it looked the next morning.
On June 11, both of my legs buckled and I fell down. On July 25, my husbands leg buckled several times and has had reoccurring muscle spasms in both arms for 1 minute ~ 6X since vaccination and my son's leg buckled yesterday, July 27, and he fell requiring 6 staples in his head. We all had the J&J on the same day and are healthy.
Severe pain from top of shoulder to upper left deltoid where IM shot given. No redness or swelling. Symptoms continued for 1 week. Full ROM to arm.
Chills. Fever , headache, fatigue, body aches within 14 hours of shot. Red, sore, and warm area 3? around shot after 48 hours
First dose of DTaP given on 10/26/11.  Extremely crabby (could not put him down), poor appetite, restlsess, poor sleeping patterns at night on 10/27 & 10/28.  On 10/28 he vomited once in the evening.  I called the after hours exchange number.  Fever set in on 10/29 and persisted on and off until the evening of 10/30 (Tylenol was given as necessary).  Back to self on 10/31.
Client received vaccines at 8:15 am. 13:00 experienced chest pain. Middle of the night he felt chest pain and throat felt close, coughed and spit up a little blood. Return to clinic 8:15 next day no local reaction noted no further symptoms.
Information has been received from a pharmacist referring to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions/allergies and concomitant medication were not reported. The pharmacist stated that the patient potentially received an expired dose of ZOSTAVAX (lot #, expiration date, route and dose were unknown) on an unknown date. The pharmacist was investigating if this dose was actually administered. No adverse effects were reported. Additional information has been requested.
few drops of the vaccine dripped from their arms; a few drops fell onto her skin while injecting; few drops of the vaccine dripped from their arms like when they got the vaccine not all of that went in; This is a spontaneous report from a contactable Pharmacist. This pharmacist (reported on behalf of the patient)  A 46-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Formulation: Solution for Injection, Lot number: EW0182; Expiration date: 31Aug2021), via unknown route of administration on an unknown date at an unknown dose as single dose for COVID-19 immunisation. Patient medical history and concomitant medications were not reported.  Reporter informed that after administering the COVID vaccine, few drops of the vaccine dripped from their arms like when they got the vaccine (dripped of the vaccine slide down their arms), not all of that went in. Patient wanted to know what the process to follow. Reporter queried to know if the patient need get their vaccine repeated or what needs to be done. No further probing could be done as the consumer (patient) was unwilling to share any further information. Hence limited information available over the call. Reporter seriousness was Unspecified.    Information on Lot/Batch number was available. Additional information has been requested.  Follow-Up (01Jun2021): Follow-up attempts are completed. No further information is expected.  Amendment (30May2021): This follow-up report is being submitted to amend previously reported Information: Added event, Exposure via skin contact.
had covid back in July 2022 with fever; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (had covid back in July 2022 with fever) in a 72-year-old patient of an unknown gender who received mRNA-1273 (Spikevax) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 29-Jul-2022, the patient experienced COVID-19 (had covid back in July 2022 with fever). At the time of the report, COVID-19 (had covid back in July 2022 with fever) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.   For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication details not reported by the reporter. Treatment details was not reported by the reporter.   Reporter did not allow further contact
My daughter has been to many specialists over the past few years trying to troubleshooting her illness. She has always been very active in sports and a very outgoing child. We noticed some "differences" around age 15, always tired, body aches etc but thought it was her growing. The summer of 2013 she seemed have a hard time breathing after running and physical activity. In Oct.2013 she couldn't keep running during basketball would have what some assumed was sports asthma, we had her tested and test came back she did not have sports asthma, body and joint aches came with this. Step followed and we had her tonsils removed thinking they were too big and possibly restricting her breathing. This occurred in Dec. 2013. She complained of severe chest pains on multiple occasions and had a hard time breathing during the day at normal rest. In Feb/March 2014 we had an EKG done at hospital, test came back everything was ok. We have had her check for allergies those test came back ok also. We have been seeing specialist at a specialist hospital and they have diagnosed her with P.O.T.S. syndrome.  Postural Orthostatic Tachycardia Syndrome. Patient has had severe migraines, trouble waking, body aches daily, a hard time focusing, stomach and digestive issues just to name a few of her everyday symptoms.
Incapacitating myalgia; Fever; This case was reported by a other health professional via call center representative and described the occurrence of myalgia in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced myalgia and fever. On an unknown date, the outcome of the myalgia and fever were unknown.   It was unknown if the reporter considered the myalgia and fever to be related to Shingrix.     Additional Information: GSK Receipt Date: 06-Jan-2023. Reporter's Comments: The reporter stated that the patient had severe symptoms after the patient had received the first dose of Shingrix approximately 4 months ago from reporting.  The patient seemed to have had presented incapacitating myalgia and fever.  No information about the vaccine or more information about the patient was disclosed. The reporter gave consent to follow up.
This spontaneous report was received from a physician via company representative, concerning a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant therapies were not reported. On 19-JAN-2016, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 (lot number L024129; expiration date 21-JAN-2017) "10 PK 0.5 ml SD-PFS LLok w tip" (route of administration and anatomical location were not reported). On an unspecified dates, the PNEUMOVAX 23 had one temperature excursion of 120 hours. The highest recorded temperature was 34 F (1.111111111). No adverse effects reported and no product quality complaint was involved. The vaccine status was reported as "in excursion". The vaccine storage criteria and the storage type of excursion were reported as "Refrigerator (R)". This is one of several cases from the same reporter. Additional information has been requested.
I had pain at the injection site and a headache the following day after the shot then I thought I was back to normal. The following Saturday I started to feel itchy and I have a measles or chickenpox looking rash on both arms. Some of the small bumps are red.
Pt was given two doses of Hep. B vaccine  on 7/18/2019 Pt has had NO immediate adverse reaction/event.
Follow up at 19Mo old for well child visit. Vaccination ordered by Dr.  DTap 0.5mg given in the LVL by IM injection Manufacturer Sanofi-Pasteur Lot#65065AA Exp 10/8/18. After vaccine, patients left thigh swell up into large hive. Mom brought him back from parking lot to be checked. No respiratory problems, lungs-clear. Benadryl 7.5 ml given in office. Follow up call at 12:26 baby is sleeping and hive is a little smaller. The following medication was given: Medication: Diphenhist, hcl  Dose: 12.5mg/5mL Quantity: 7.5mL.
12 days after mmr shot he had high fevers for two days went to ER brought temp down next day high fever again.  Scheduled pediatrician office visit that day and the Doctor told us it was probably a reaction to the shots MMR.  He said we would probably notice a rash also and he now has the rash.
Numbing sensation in face, cheecks, forehead; Numbness in lips and tongue; Slight puffiness in face; Pain at the injection site, still painful; Injection site are is raised; Injection site is red; Can only lift arm to the height of shoulder; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 57-year-old female patient who received Flu Seasonal QIV  (FluLaval Quadrivalent 2022-2023 season) (batch number 24R5E, expiry date 29th June 2023) for prophylaxis.   Co-suspect products included flu seasonal qiv pre-filled syringe device (Flulaval Tetra Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included prednisone. Concurrent medical conditions included psoriatic plaque. Concomitant products included ustekinumab (Stelara).   On 8th September 2022, the patient received FluLaval Quadrivalent 2022-2023 season and Flulaval Tetra Pre-Filled Syringe Device. On 8th September 2022, immediately after receiving FluLaval Quadrivalent 2022-2023 season and Flulaval Tetra Pre-Filled Syringe Device and immediately after starting FluLaval Quadrivalent 2022-2023 season and Flulaval Tetra Pre-Filled Syringe Device, the patient experienced injection site pain, injection site swelling, injection site erythema and injected limb mobility decreased. On 9th September 2022, the patient experienced numbness facial, hypoesthesia oral and facial puffiness. The patient was treated with prednisone and non-drug therapy (Ice Pack (No Medication)). On an unknown date, the outcome of the injection site pain, injection site swelling, injection site erythema, injected limb mobility decreased, numbness facial, hypoesthesia oral and facial puffiness were not recovered/not resolved.   It was unknown if the reporter considered the injection site pain, injection site swelling, injection site erythema, injected limb mobility decreased, numbness facial, hypoesthesia oral and facial puffiness to be related to FluLaval Quadrivalent 2022-2023 season and Flulaval Tetra Pre-Filled Syringe Device.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 24-OCT-2022 Reporter's Comment: Reporter is patient. The patient stated that received Flulaval on left arm. Immediately, patient experienced pain at the injection site area is red, raised, and is still painful.  The patient could only lift her arm to the height of her shoulder without experiencing pain. One day after, patient experienced a numbing sensation in her face had numbness in her cheeks and forehead, which come and go, but the numbness in her lips and tongue endure. Patient had slight puffiness on face. The patient has been treated with 2 rounds of a prednisone taper, and patient has been applying ice to her arm. Patient was scheduled to have an MRI this week. Reporter gave consent to follow up with HCP.
Patient was given 1 ml dose of covid 19 vaccine (Moderna).  The correct dose is 0.5ml. No adverse effects were reported. This was discovered shortly after the vaccine was administered.
Aches, Pains, Fatigue and pain at injection site without fever for four days. Pain at injection site ongoing to this date.  Unable to move without pain in arm where injection was administered.
Headache after 2nd dose; Sore arm after 2nd dose; Hives from head to toes after 2nd dose; Fatigue after 2nd dose; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm after 2nd dose), URTICARIA (Hives from head to toes after 2nd dose), FATIGUE (Fatigue after 2nd dose) and HEADACHE (Headache after 2nd dose) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032b21a) for COVID-19 vaccination.     Previously administered products included for Hives: SHINGRIX VACCINE.    On 08-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Sore arm after 2nd dose), URTICARIA (Hives from head to toes after 2nd dose), FATIGUE (Fatigue after 2nd dose) and HEADACHE (Headache after 2nd dose). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at a dose of 1 dosage form; DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL ITCH) at a dose of 1 dosage form. At the time of the report, PAIN IN EXTREMITY (Sore arm after 2nd dose), URTICARIA (Hives from head to toes after 2nd dose), FATIGUE (Fatigue after 2nd dose) and HEADACHE (Headache after 2nd dose) outcome was unknown.            This case was linked to US-MODERNATX, INC.-MOD-2021-079285 (E2B Linked Report).; Sender's Comments:  -MODERNATX, INC.-MOD-2021-079285:
Feeling weaker than usual, ran fever 103, pain under chin & cheeks next a.m. & swelling of cheeks. Symptoms still present at time of writing this report. Also fighting asthma at this time. Fever subsided in last 2 days, with Tylenol, temp around 100.2.
everything was spinning around me; lose balance; felt confused; light-headed/  dizzy; headache; pain in my arm; This is a spontaneous report received from a contactable consumer (reporting on herself). A 51-years-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, lot number and Expiry date was not reported), via an unspecified route of administration on 18Apr2021 as single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient previously took mercurochrome and experienced drug hypersensitivity. It was reported that she received the first dose of the BNT162B2 vaccine on Sunday (18Apr2021), that day she felt confused, light-headed, she had a headache and pain in her arm, but she considered that normal. At night, she woke up at 3 am (on 19Apr2021), she felt really dizzy, everything was spinning around her, she loose balance. she needed to go to the bathroom, but she had to walk holding herself in the walls, right now she still dizzy, she allergic to mercurochrome. Patient was 51 years old and asking when will it go away. The outcome of the events was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
approx 4-5hr p/vax lt thigh-devel purpura of both lower extremities including feet;only on anterior surface of legs;feet appeared purplish-purpura was still present next day but less dramatic;
This spontaneous report as received from a healthcare professional refers to an unspecified number of patients. The patients medical history was not reported. On an unknown dates, the patients received doses of PNEUMOVAX 23 (lot #, dose, route and site of administration were not reported) that were improperly stored. No adverse experiences were reported. This is one of several reports from the same reporter. Additional information has been requested.
I95.9 HYPOTENSION 3/23/2023 NEAR SYNCOPE
I have been tracking my menstrual cycle for several months. Ovulation occurred 4 days later than normal this month.
chronic pain; Pain level extremely high feels like someone is cutting her arm; Burning from shoulder all the way down to the hand; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PAIN IN EXTREMITY (Pain level extremely high feels like someone is cutting her arm), BURNING SENSATION (Burning from shoulder all the way down to the hand) and PAIN (chronic pain) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016M20A and 047A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 17-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 18-Mar-2021, the patient experienced PAIN IN EXTREMITY (Pain level extremely high feels like someone is cutting her arm) and BURNING SENSATION (Burning from shoulder all the way down to the hand). On 07-Apr-2021, the patient experienced PAIN (chronic pain). The patient was treated with Physical therapy for Pain in extremity and Physical therapy for Pain. At the time of the report, PAIN IN EXTREMITY (Pain level extremely high feels like someone is cutting her arm), BURNING SENSATION (Burning from shoulder all the way down to the hand) and PAIN (chronic pain) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       person states that second dose was administered with a very large needle. She was not sure if it was given to her in the muscle. person stated that the person who administered the dose did not used an alcohol swipe before injecting her with the needle. Patient took X-ray and Ultra sound. There was a chronic inflammation indicated. Administered a medicinal injection to relieve the area. Treatment medications include Tylenol and Ibuprofen.   Most recent FOLLOW-UP information incorporated above includes: On 12-May-2021: non significant follow up
On day 2 after receiving the vaccine, I had severe headache, low grade fever, body aches and chills. This only lasted until the end of the day. For the following week, I had mild to moderate headache on and off that was mostly located in the back/bottom of my scalp. Once the headache subsided, I had aches in the back/bottom of my scalp that worsened over the next few days. By day 8, the pain in the back of my head was now in my neck and left shoulder. Pain was 8/10. On day 9, I was advised by an on-call nurse to visit the ER, where a doctor told me I had an enlarged lymph node in my neck. I have been taking Flexeril for 8 days (10 mg) and Tylenol (500-1000 mg) as needed, as well as using heat on the area for 20 minutes each hour. Over the last few days, the skin on my left back shoulder and on my bicep where the injection was administered has become painful to the touch, but not red or irritated. I also now have mild soreness in my left pectoral muscle. No symptoms have subsided at this point.
No additional AE; MMR II was improperly stored then administered; This spontaneous report was received from a medical assistant, referring to a patient of unknown gender and age. The patient's pertinent medical history, concurrent conditions, concomitant therapies and previous drug reactions or allergies were not provided.  On 11-AUG-2020, the patient was vaccinated with an improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (rHA) (M-M-R II), at a dose of 0.5 milligrams (ml) (stenght, vaccination scheme frequency, route of administration, and anatomical site of vaccination were not reported; lot number S022753 has been verified to be valid, expiration date reported and validated as 22-JUL-2021) as prophylaxis (product storage error).  The administered dose of the vaccine experienced a temperature of 27.44 degrees Fahrenheit (F) for 5 hours and 30 minutes, as recorded by a data logger. No previous temperature excursion was reported. There was no adverse effect reported.